HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02
Status:
Terminated
Trial end date:
2016-12-30
Target enrollment:
Participant gender:
Summary
This study, HALO-DMD-03, is a follow-on study to HALO-DMD-01 and HALO-DMD-02, and allows
continued open-label access to HT-100 for subjects who have completed these studies.
HALO-DMD-03 will provide safety and strength and function data on continuous long-term
dosing. Data from this study will be used to inform the safety, tolerability, and dose
selection for a future trial of HT-100 in boys with Duchenne Muscular Dystrophy (DMD).